EWOC 2.0: Interactive software for dose escalation in cancer phase I clinical trials

Drug Information Journal

Volumn 41, Issue 2, 2007, Pages 221-228

  Xu, Zhiheng ^a,b   Tighiouart, Mourad ^a,b   Rogatko, André ^a,b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bayesian feasibility; Bayesian method; Dose limiting toxicity; Maximum tolerated dose

Indexed keywords

BAYES THEOREM; CANCER RESEARCH; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG DOSE INCREASE; MAXIMUM TOLERATED DOSE; METHODOLOGY; PRIORITY JOURNAL;

EID: 33947263070     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100216     Document Type: Conference Paper

References (18)

1. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase 1. Clin Cancer Res. 2005;11:5342-5346.
2. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46: 33-48.
3. Eichhorn BH, Zacks S. Sequential search of an optimal dosage, I. J Am Stat Assoc. 1973;68:594-598.
4. Rogatko A, Babb JS. Escalation With Overdose Control, User's Guide. Version 1.beta. Available at: http://www.fccc.edu/users/rogatko/ewoc. html. Accessed July 10, 2005.
5. Rogatko A, Tighiouart M, Xu Z. Escalation With Overdose Control. Version 2.0. Available at: http:// sisyphus.emory.edu/ewoc.html. Accessed January 12, 2006.
6. Wooley PV, Schein PS. Methods Cancer Research. New York, NY; Academic Press; 1979.
7. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103-1120.
8. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Stat Med. 2002;21:2757-2770.
9. Tighiouart M, Rogatko A, Babb JS. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med. 2005;24:2183-2196.
10. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS Version 1.2 User Manual. Cambridge, UK: MRC Biostatistics Unit; 1999.
11. Rosenberger WF, Canfield GC, Perevozskaya I, Haines LM, Hausner P. Development of interactive software for Bayesian optimal phase I clinical trial design. Drug Inf J. 2005;39:89-98.
12. Whitehead J, Patterson S, Webber D, Francis S, Zhou Y. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics. 2001;2:47-61.
13. Fortran N. NAG Fortran Library Routine Document. Available at: http://www.nag.com/numeric/ fl/manual/pdf/D01/d01_conts.pdf. Accessed January 12, 2006.
14. Patterson TNL. On some Gauss and Lobatto based integration formulae. Math Comput. 1968; 22:877-881.
15. Patterson TNL. The optimum addition of points to quadrature formulae, errata. Math Comput. 1969;23:877-881.
16. Babb J, Rogatko A. Bayesian methods for cancer phase 1 clinical trials. In: Geller N, ed. Contemporary Biostatistical Methods in Clinical Trial. New York, NY: Marcel Dekker; 2004:1-39.
17. Haines LM, Perevozskaya I, Rosenberger WF. Bayesian optimal designs for phase I clinical trials. Biometrics. 2003;59:591-600.
18. Tighiouart M, Rogatko, A. Dose finding in oncology-parametric methods. In: Ting N, ed. Dose Finding in Drug Development. New York, NY: Springer; 2006:59-72.